Asston Pharmaceuticals IPO GMP – Complete Details at a Glance
Company Introduction
Asston Pharmaceuticals Limited is an emerging pharmaceutical company, founded in 2019. The company manufactures a wide range of medicines such as tablets, capsules, syrups, sachets, and creams, and supplies these to domestic as well as international markets. The company is also active in the field of nutraceuticals and operates on a contract manufacturing model for several products.
Asston Pharmaceuticals IPO GMP
Asston Pharmaceuticals IPO GMP remains a key discussion topic among investors. The grey market premium (GMP) indicates how much premium the company's shares are getting in the unofficial market before listing.
Day 1 (on the day of IPO opening): GMP around ₹10
Day 2: GMP rose to ₹30, indicating that investors have positive sentiments about the IPO.
This makes it likely that the company's listing price may be significantly higher than the issue price.
IPO Overview
IPO Type: SME IPO (Book-built issue)
Issue Size: ₹27.56 crore (Total 22.41 lakh shares)
Face Value: ₹10 per share
Price Band: ₹115 to ₹123 per share
Lot Size: 1000 shares
Minimum Investment (Retail): ₹2,46,000 (2 lots 2000 shares)
HNI Investment: Minimum 3 lots ₹3,69,000
Asston Pharmaceuticals IPO Timeline
Below is the complete timeline of Asston Pharmaceuticals IPO (as available in Finowings is):
IPO Opening Date: 09 July 2025
IPO Closing Date: 11 July 2025
Share Allotment Date: 14 July 2025
Refund Start Date: 15 July 2025
Share Credit in Demat Account: 15 July 2025
Listing Date (Expected): 16 July 2025
Financial Performance
The company has shown tremendous growth in the last few years. In FY2025:
Revenue: ₹25.61 crore — nearly 60% YoY growth
Net Profit (PAT): ₹4.32 crore — over 200% growth
This performance is a reliable signal for investors.
Use of Funds (Objects of the Issue)
The company will use the funds raised from the IPO for the following purposes:
Purchase of new machinery for the manufacturing unit
Meeting working capital requirements
Repayment of certain debts
For general corporate needs
Lead Manager and Registrar
Lead Manager: Sobhagya Capital Options Limited
Registrar: Maashitla Securities Private Limited
Market Maker: JSK Securities and Services Private Limited
Conclusion
The current status of Asston Pharmaceuticals IPO GMP indicates that investors are positive about it. Strong financials, clear fund utilization, and accurate price band make this an attractive SME IPO. Although the SME segment is volatile, growth-oriented investors can look at this as an opportunity.
Comments
0 comment